Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.
Korner
Judith
J
Lo
Janet
J
Freda
Pamela U
PU
Wardlaw
Sharon L
SL
D019440:Anti-Obesity Agents; D000077465:Cabergoline; D004873:Ergolines / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008297:Male; D015431:Weight Loss
D019440:Anti-Obesity Agents; D004873:Ergolines; D000077465:Cabergoline